

Abstract

The Development of an Early Diagnostic Method for Alzheimer's Disease [†]

Yulia K. Styuflyeva ^{1,2,*}, Andrew A. Zelinsky ² , Oksana A. Malikova ² and Aleksandr A. Rubel ² 

¹ SCAMT Institute, ITMO University, 197101 St. Petersburg, Russia

² Laboratory of Amyloid Biology, St. Petersburg State University, 199034 St. Petersburg, Russia; andrew_zelinsky@mail.ru (A.A.Z.); oks_malik@mail.ru (O.A.M.); arubel@mail.ru (A.A.R.)

* Correspondence: styuflyeva@scamt-itmo.ru

[†] Presented at the 3rd International Electronic Conference on Biomolecules, 23–25 April 2024; Available online: <https://sciforum.net/event/IECBM2024>.

Keywords: Alzheimer's Disease (AD); aggregates; amyloid beta (A β); Protein Misfolding Cyclic Amplification (PMCA); neuronal degeneration

Alzheimer's disease (AD) is the most common form of dementia, characterized by neuronal degeneration and death. The appearance of aggregated forms of the A β 42 peptide is a key biochemical marker indicating the possible initiation of the pathological cascade in Alzheimer's disease [1].

The goal of this study is to develop an approach for the early diagnosis of AD by detecting A β 42 multimers in the blood and lymph.

We adapted the Protein Misfolding Cyclic Amplification (PMCA) method [2] for the detection of A β 42 aggregates in blood samples. One of the main challenges in using the PMCA method for detecting A β 42 aggregates is that the synthesized or recombinant A β 42 peptide spontaneously aggregates with high yield. Therefore, it is difficult to distinguish spontaneous aggregation from aggregation induced by externally added aggregated A β 42, e.g., from the patient's samples.

Previously, using a yeast model [3], we identified mutations in human A β 42 that reduce its aggregation propensity. In this study, we isolated and purified the wild-type A β 42 and five recombinant A β 42 variants with mutations that decrease A β 42 aggregation via metal-affinity chromatography. We investigated the aggregation kinetics of these A β 42 variants in the presence of thioflavin T using fluorometry. Currently, we are studying the aggregation kinetics of different A β 42 variants in the presence of aggregated wild-type A β 42.

We believe that our findings will help develop an effective system for detecting multimeric forms of the A β peptide in the blood at extremely low levels to be used as a biomarker for diagnosing AD before the onset of any clinical symptoms.

Author Contributions: Conceptualization, A.A.R.; data acquisition and formal analysis, Y.K.S., A.A.Z. and O.A.M.; supervision, A.A.R.; funding acquisition, A.A.R.; writing—review and editing, Y.K.S. and A.A.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by St. Petersburg State University (project No. 95444727).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors acknowledge Yury O. Chernoff, for valuable comments and Core Facility "Chromas" (Research Park, St. Petersburg State University) for technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.



Citation: Styuflyeva, Y.K.; Zelinsky, A.A.; Malikova, O.A.; Rubel, A.A. The Development of an Early Diagnostic Method for Alzheimer's Disease.

Proceedings **2024**, *103*, 83.

<https://doi.org/10.3390/proceedings2024103083>

Academic Editor: Jurg Bahler

Published: 12 April 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

References

1. Kulichikhin, K.Y.; Malikova, O.A.; Zobnina, A.E.; Zalutskaya, N.M.; Rubel, A.A. Interaction of Proteins Involved in Neuronal Proteinopathies. *Life* **2023**, *13*, 1954. [[CrossRef](#)] [[PubMed](#)]
2. Castilla, J.; Saá, P.; Morales, R.; Abid, K.; Maundrel, K.; Soto, C. Protein misfolding cyclic amplification for diagnosis and prion propagation studies. *Methods Enzymol.* **2006**, *412*, 3–21. [[CrossRef](#)] [[PubMed](#)]
3. Chandramowlishwaran, P.; Sun, M.; Casey, K.L.; Romanyuk, A.V.; Grizel, A.V.; Sopova, J.V.; Rubel, A.A.; Nussbaum-Krammer, C.; Vorberg, I.M.; Chernoff, Y.O. Mammalian amyloidogenic proteins promote prion nucleation in yeast. *J. Biol. Chem.* **2018**, *293*, 3436–3450. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.